title: Expression of secretory leukocyte protease inhibitor detected by immunohistochemistry correlating with prognosis and metastasis in colorectal cancer.
abstract: BACKGROUND
  The potential of secretory leukocyte protease inhibitor (SLPI) as a biomarker for colorectal cancer was studied. A prospective, randomized, controlled, clinical trial was conducted in 2013 and 2014 to confirm whether the expression of SLPI correlates with prognosis and metastasis in colorectal cancer patients.
  
  
  METHODS
  Immunohistochemistry was used to detect SLPI expression in colorectal cancer. The expression of SLPI was scored by two pathologists independently. Statistical analysis of the data was performed using a Χ2 test to investigate the influence of SLPI on the pathologic characteristics of colorectal cancer.
  
  
  RESULTS
  Compared with normal tissue, SLPI was overexpressed in colorectal cancer tissue. Overexpression of SLPI correlated with different grades (moderate or good differentiation: 2.7% low expression versus 97.3% high expression, low differentiation: 41.7% low expression versus 58.3% high expression), TNM stage (I or II: 4.2% low expression versus 95.8% high expression; III or IV: 19.7% low expression versus 80.3% high expression), lymphatic metastasis (18.6% low expression versus 81.4% high expression) and distal metastasis (86.5% low expression versus 13.5% high expression), but not with patient age or sex (P=0.613, P=0.871).
  
  
  CONCLUSIONS
  Upregulated SLPI correlates with aggressive pathologic characteristics of colorectal cancer; SLPI could be used as an indicator of progression and metastasis in patients with colorectal cancer.
authors.affiliation: Department of Delivery Room, Cangzhou Central Hospital, 16 Xinhua West Road, Yunhe District, Cangzhou City, Hebei Province 061001, People's Republic of China. guiyingliu@yeah.net.
authors.forename: Guiying
authors.initials: G
authors.lastname: Liu
authors.forename: Jingyan
authors.initials: J
authors.lastname: Yang
authors.forename: Yulei
authors.initials: Y
authors.lastname: Zhao
authors.forename: Zhijing
authors.initials: Z
authors.lastname: Wang
authors.forename: Baoheng
authors.initials: B
authors.lastname: Xing
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Dongliang
authors.initials: D
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000378:metabolism*; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor